Evaluation of Anticancer Activity of Curcumin Analogues Bearing a Heterocyclic Nucleus

  • Ahsan, Mohamed Jawed (Department of Pharmaceutical Chemistry, Maharishi Arvind College of Pharmacy)
  • Published : 2016.06.01


We report herein an in vitro anticancer evaluation of a series of seven curcumin analogues (3a-g). The National Cancer Institute (NCI US) Protocol was followed and all the compounds were evaluated for their anticancer activity on nine different panels (leukemia, non small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer) represented by 60 NCI human cancer cell lines. All the compounds showed significant anticancer activity in one dose assay (drug concentration $10{\mu}M$) and hence were evaluated further in five dose assays (0.01, 0.1, 1, 10 and $100{\mu}M$) and three dose related parameters $GI_{50}$, TGI and $LC_{50}$ were calculated for each (3a-g) in micro molar drug concentrations (${\mu}M$). The compound 3d (NSC 757927) showed maximum mean percent growth inhibition (PGI) of 112.2%, while compound 3g (NSC 763374) showed less mean PGI of 40.1% in the one dose assay. The maximum anticancer activity was observed with the SR (leukemia) cell line with a $GI_{50}$ of $0.03{\mu}M$. The calculated average sensitivity of all cell lines of a particular subpanel toward the test agent showed that all the curcumin analogues showed maximum activity on leukemia cell lines with $GI_{50}$ values between 0.23 and $2.67{\mu}M$.


  1. Ahsan MJ, Khalilullah H, Yasmin S, et al (2013). Synthesis, characterisation, and in vitro anticancer activity of curcumin analogues bearing pyrazole/pyrimidine ring targeting EGFR tyrosine kinase. BioMed Res Int, Article ID 239354.
  2. Alley MC, Scudiero DA, Monks PA, et al (1998). Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res, 48, 589-01
  3. Aydemir, N, Bilaloglu, R (2003). Genotoxicity of two anticancer drugs, gemcitabine and topotecan, in mouse bone marrow in vivo. Mutat Res, 537, 43-51.
  4. Balaji SN, Ahsan MJ, Jadav SS, et al (2015). Molecular modeling, synthesis and antimalarial potentials of curcumin analogues containing heterocyclic ring. Arab J Chem, (in Press).
  5. Boyd MR, Paull KD (1995). Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res, 34, 91-109
  6. Corona P, Carta A, Loriga M, et al (2009). Synthesis and in-vitro antitumor activity of new quinoxaline derivatives. Eur J Med Chem, 44, 1579-91.
  7. Grever MR, Schepartz SA, Chabner BA (1992). The National Cancer Institute: cancer drug discovery and development program. Seminars Oncol, 19, 622-38
  8. (Retrieved on 15th December 2015)
  9. (Retrieved on 11th November 2015)
  10. Jia Y, Li J, Qin ZH, et al (2009). Autophagic and apoptotic mechanisms of curcumin-induced death in K562 cells. J Asian Nat Prod Res, 11, 918-28
  11. Kunwar A, Barik A, Mishra B, et al (2008). Phytochemicals as modulators of neoplastic phenotypes. Biochem Biophy Act, 1780, 673-9
  12. Lal J, Gupta SK, Thavaselvam D, et al (2012). Design, synthesis, synergistic antimicrobial activity and cytotoxicity of 4-aryl substituted 3,4-dihydropyrimidinones of curcumin. Bioorg Med Chem, 22, 2872-6
  13. Liang G, Shao L, Wang Y, et al (2009). Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem, 17, 2623-31.
  14. Mishra S, Karmodiya K, Surolia N, et al (2008). Synthesis and exploration of novel curcumin analogues as anti-malarial agents. Bioorg Med Chem, 16, 2894-02.
  15. Monks A, Scudiero D, Skehan P, et al (1991). Feasibility of a high-flux anticancer drug screening using a diverse panel of cultured human tumor cell lines. J National Cancer Inst, 83, 757-66
  16. Paul NK, Jha M, Bhullar KS, et al (2014). All trans 1-(3-arylacryloyl)-3,5-bis (pyridin-4-ylmethylene) piperidin-4-ones as curcumin-inspired antineoplastics. Eur J Med Chem, 87, 461-70.
  17. Sahu PK, Sahu PK, Gupta SK, et al (2012). Synthesis and evaluation of antimicrobial activity of 4H-pyrimido[2,1-b] benzothiazole, pyrazole and benzylidene derivatives of curcumin. Eur J Med Chem, 54, 366-78
  18. Saja K, Babu MS, Karunagaran D, et al (2007). Antiinflammatory effect of curcumin involves down regulation of MMP-9 in blood mononuclear cells. Int Immunopharm, 7, 1659-67
  19. Sharma R, Jadav SS, Yasmin S, et al (2015). Simple efficient and improved synthesis of Biginelli-type compounds of curcumin as anticancer agents. Med Chem Res, 24, 236-44
  20. Shoemaker RH (2006). The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer, 6, 813-23.
  21. Siegel RL, Miller DK, Jemal A (2015). Cancer Statistics, 2015. CA Cancer J Clin, 65, 5-29.
  22. Singh RK, Rai D, Yadav D, et al (2010). Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid. Eur J Med Chem, 45, 1078-86.
  23. Takiar R, Nadiyal D, Nandakumar A (2010). Projections of number of cancer cases in India (2010-2020) by cancer groups. Asia Pac J Cancer Prev, 11, 1045-9.
  24. Vyas A, Dandawate P, Padhye S, et al (2013). Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Curr Pharm Des, 19, 2047-69.
  25. WHO World Cancer Report (2014). Retrieved from (Retrieved on 12 December 2014).
  26. Yadav IS, Nandekar PP, Shrivastava S, et al (2014). Ensemble docking and molecular dynamics identify knoevenagel curcumin derivatives with potent anti-EGFR activity. Gene, 539, 82-90.
  27. Zhichang L, Yinghong W, Yuanqin Z, et al (2012). Synthesis and antibacterial activities of N-substituted pyrazole curcumin derivatives. Chinese J Org Chem, 32, 1487-92.